§ Total number of reported laboratory-positive dengue cases, including all confirmed cases [by anti-dengue virus (DENV) molecular diagnostic methods or seroconversion of anti-DENV IgM] and all probable cases (by a single, positive anti-DENV IgM).
** Includes drug resistant and susceptible cases of Invasive Pneumococcal Disease. This condition was previously named Streptococcus pneumoniae invasive disease and cases were reported to CDC using different event codes to specify whether the cases were drug resistant or in a defined age group, such as <5 years.
†† Includes Escherichia coli O157:H7 and Shiga toxin-positive Escherichia coli (including O157, non-O157, and not serogrouped).
§§ Data reported to ArboNET using the national surveillance case definition for congenital Zika virus disease or infection (CSTE Position Statement 16-ID-01). Additional data reported to the US Zika Pregnancy Registry for outcomes of pregnancies with laboratory evidence of possible Zika virus infection are available at https://www.cdc.gov/pregnancy/zika/data/pregnancy-outcomes.html. Cases reported to the US Zika Pregnancy Registry might not meet the national surveillance case definition for congenital Zika virus disease or infection.
These are annual cases of selected infectious
national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS).
NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are
collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets
may be updated as additional information is received, statistics in publications based on that source data may
differ from what is presented in these tables.
The list of nationally notifiable infectious diseases and conditions for 2018 and their national surveillance case definitions are
available by navigating to the Surveillance Case Definitions | CDC web page, selecting
"2017" for the notifiable condition list year, checking "infectious" conditions, and clicking "Get Notifiable List by Year".
This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved in 2016 by CSTE
for national surveillance, that were implemented in January 2017, including updated surveillance case definitions for
salmonellosis, shigellosis, vibrioisis, perinatal hepatitis B virus infection, invasive pneumococcal disease, Lyme disease,
and tularemia reported through August 7, 2018. Publication criteria for the finalized 2017 data are available at
Guide to Interpreting Provisional and Finalized NNDSS Data.
Population estimates for incidence rates are July 1st, 2017 estimates obtained from the National Center for Health Statistics (NCHS)
postcensal estimates of the resident population of the United States for April 1, 2010 - July 1, 2017, by year, county, single year
of age (range: 0 to 85 years), bridged-race (white, black or African American, American Indian or Alaska Native, Asian,
or Pacific Islander), Hispanic ethnicity (not Hispanic or Latino, Hispanic or Latino), and sex (Vintage 2017),
prepared under a collaborative arrangement with the U.S. Census Bureau. Population estimates for states released
June 27, 2018 are available at
Population estimates for territories are the 2017 mid-year estimates from the U.S. Census Bureau International Data Base, accessed on
October 2, 2018 at
The choice of population denominators
for incidence is based on the availability of population data at the time of publication preparation.
Annual tables for 2016 and later years are available on CDC WONDER.
Annual summary reports from 1993-2015 are available as published in the
NNDSS annual tables since 1952 are available at CDC Stacks
(once in CDC Stacks select "Annual Reports" in the "Genre" box to the left).